
Real-world data provides the opportunity to enhance regulatory decisions for new drugs
19 February 2020
- Real-world data and evidence provide valuable performance data on a post-approval drug to create a comprehensive clinical snapshot
- This can later support regulatory and reimbursement decisions and clinical guidelines
- More and more stakeholders in the pharmaceutical pipeline are recognising the value of real-world data
Click here to learn more
About SVMPharma
SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com
ref: FEB2020LN001